Can targeting inflammation slow aging or reduce cardiovascular risk?

BGE-102 inhibits NLRP3, an inflammatory signaling complex, and is being tested as an oral treatment. BioAge reported large short-term reductions in hsCRP in phase 1 participants with obesity and elevated inflammation. That is a measurable pharmacological effect and a reason to study the compound further. The phase 2 program includes people with elevated cardiovascular risk as well as a separate retinal-disease program; their endpoints should be evaluated independently.[1][2]

A lower inflammatory marker is not the same as a longer life or fewer heart attacks. Biomarkers can identify risk or demonstrate target activity without fully predicting the net effect of a medicine. Long-term benefit also depends on adverse effects and the population treated. The available early reports do not establish an anti-aging treatment or cognitive enhancer. For a future efficacy claim, look for controlled clinical outcomes and adequate follow-up rather than interpreting an hsCRP percentage as a lifespan effect.[1][2]